-
Javier Pinilla-Ibarz, MD, PhD; Moffit Cancer Center; 5Live #ASH21
12:43
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Jennifer Woyach, MD; Ohio State; 5Live #ASH21
5:16
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Matthew Davids, MD, MMSc; Dana-Farber Cancer Institute; 5Live #ASH21
5:39
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Nitin Jain, MD: The University of Texas MD Anderson Cancer Center: 5Live #ASH21
4:19
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Jennifer Brown, MD, PhD; Dana-Farber Cancer Institute; 5Live #ASH21
7:18
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Tara Graff, DO, MS: Mission Cancer and Blood; 5Live #ASH21
6:51
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
BTK inhibitors vs BCL2 inhibitors in untreated CLL_Susan O'Brien, MD; #DDHO2021
2:30
-
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
15:33
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
-
Nicole Lamanna, MD; Columbia University #BtC_ASCO21
16:56
Dr. Nicole Lamanna discusses Practical Issues in Treating CLL: Sequencing, Oral Adherence, Managing Adverse Events, and MRD Analysis.
-
Matthew Davids, MD, MMSc; Dana-Farber Cancer Inst. #BtC_ASCO21
15:27
Dr. Matthew Davids reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for CLL.
-
William G. Wierda, M.D., Ph.D.; The University of Texas MD Anderson Cancer Center; 5Live; #ASCO2021
5:42
- Next Page